Testing CC312 for people with autoimmune diseases
Treatments studied
Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Skin clinical trials.
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have one of these conditions: lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia, and your disease is active despite standard treatments.
- You meet specific lab requirements for your condition, such as certain blood cell counts and kidney/liver function.
- You agree to use effective birth control during the study and for 6 months after the last dose.
- You haven't had certain prior treatments or vaccines within a specific timeframe before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This early-phase trial tests GC012F, a type of cell therapy (CAR-T), for treating autoimmune diseases. It aims to see if the treatment can safely calm the immune system and improve symptoms.
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
This early-stage trial tests whether HN2302, a new type of genetic medicine, is safe and helps patients with lupus or systemic sclerosis. Researchers want to see if it can reduce symptoms and improve organ function in people with these autoimmune conditions.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.